Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer
Portfolio Pulse from
Inhibrx Biosciences announced preliminary data from a Phase 1 trial of ozekibart (INBRX-109) for colorectal cancer treatment, showing efficacy and safety. The results were presented at the ASCO Gastrointestinal Annual Cancers Symposium.
January 21, 2025 | 10:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inhibrx Biosciences released promising preliminary data from a Phase 1 trial of ozekibart (INBRX-109) for colorectal cancer, indicating potential efficacy and safety.
The announcement of positive preliminary data from a Phase 1 trial is likely to boost investor confidence in Inhibrx's pipeline, potentially leading to a short-term increase in stock price. The presentation at a major symposium adds credibility.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100